Research programme: protozoan infection and tuberculosis therapeutics - Broad Institute/Eisai

Drug Profile

Research programme: protozoan infection and tuberculosis therapeutics - Broad Institute/Eisai

Alternative Names: Chagas disease therapeutics - Broad Institute/Eisai; Malaria therapeutics - Broad Institute/Eisai; Protein synthesis inhibitors - Broad Institute/Eisai

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Broad Institute; Eisai Co Ltd
  • Class Antimalarials; Antiprotozoals; Antituberculars; Small molecules
  • Mechanism of Action Amino acyl tRNA synthetase inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Chagas disease; Malaria; Protozoan infections; Tuberculosis

Most Recent Events

  • 22 May 2017 Eisai and the Broad Institute agree to co-develop antimalarial compounds for Malaria
  • 19 Sep 2014 Eisai and Broad Institute receive grant from Global Health Innovative Technology Fund for drug development in Malaria
  • 16 Sep 2014 Eisai and Broad Institute enter into agreement to identify novel therapeutic for the treatment of Malaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top